| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDC25B |
| Uniprot No | P30305 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-580aa |
| 氨基酸序列 | MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASS PVTTLTQTMHDLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLS SESSESSDAGLCMDSPSPMDPHMAEQTFEQAIQAASRIIRNEQFAIRRFQ SMPVRLLGHSPVLRNITNSQAPDGRRKSEAGSGAASSSGEDKENDGFVFK MPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPDRKMEVEELSP LALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKT LEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKR RRSVTPPEEQQEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAF LLQTVDGKHQDLKYISPETMVALLTGKFSNIVDKFVIVDCRYPYEYEGGH IKTAVNLPLERDAESFLLKSPIAPCSLDKRVILIFHCEFSSERGPRMCRF IRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQDYRPMNHEAF KDELKTFRLKTRSWAGERSRRELCSRLQDQ |
| 预测分子量 | 110 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC25B重组蛋白的模拟参考文献示例，供参考：
---
1. **《Purification and functional characterization of recombinant CDC25B phosphatase》**
*作者：Zhang L, et al.*
摘要：本研究通过大肠杆菌表达系统成功纯化CDC25B重组蛋白，并验证其磷酸酶活性。实验表明，重组蛋白可有效激活CDK1/cyclin B复合物，促进G2/M期转换。
2. **《Crystal structure analysis of CDC25B reveals substrate binding specificity》**
*作者：Tanaka K, et al.*
摘要：通过X射线晶体学解析CDC25B重组蛋白的催化结构域三维结构，揭示其与磷酸化底物的结合模式，为靶向抑制剂设计提供结构基础。
3. **《CDC25B overexpression enhances mitotic entry in cancer cells》**
*作者：Chen H, et al.*
摘要：在多种癌细胞系中过表达重组CDC25B蛋白，证明其异常表达导致细胞周期异常加速，与肿瘤增殖及化疗耐药性相关。
4. **《Role of CDC25B in DNA damage checkpoint bypass》**
*作者：Müller R, et al.*
摘要：利用重组CDC25B蛋白研究DNA损伤应答机制，发现其磷酸酶活性可绕过检查点调控，导致基因组不稳定性，提示潜在致癌风险。
---
注：以上文献为模拟示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
**Background of CDC25B Recombinant Protein**
CDC25B is a dual-specificity phosphatase belonging to the CDC25 family, which plays a critical role in cell cycle regulation. It primarily controls the transition from the G2 phase to mitosis by dephosphorylating and activating cyclin-dependent kinase 1 (CDK1)/cyclin B complexes. This activation removes inhibitory phosphorylation marks on CDK1. triggering mitotic entry. Dysregulation of CDC25B is linked to cancer progression, as its overexpression is observed in various tumors, correlating with poor prognosis, genomic instability, and chemoresistance.
Recombinant CDC25B protein is engineered using heterologous expression systems (e.g., *E. coli*, mammalian, or insect cells*) to produce a purified, functional form for research. Its production enables detailed studies of enzymatic activity, substrate interactions, and structural properties. Researchers utilize this recombinant protein to screen small-molecule inhibitors targeting its phosphatase domain, a strategy explored in anticancer drug development. Additionally, it serves as an antigen for antibody generation or a tool to investigate checkpoint mechanisms in cell cycle control.
Structurally, CDC25B contains an N-terminal regulatory region and a C-terminal catalytic domain. The recombinant version often includes affinity tags (e.g., His-tag) for purification and detection. Functional assays, such as *in vitro* phosphatase activity tests using fluorogenic substrates or CDK1-cyclin B complexes, validate its bioactivity.
Studying CDC25B recombinant protein provides insights into cell cycle dysregulation in diseases and aids in identifying therapeutic targets, particularly for cancers with CDC25B overexpression. Its role in DNA damage response and checkpoint recovery further underscores its relevance in oncology and molecular biology research.
×
